Toronto Dominion Bank Invests $6.76 Million in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Toronto Dominion Bank purchased a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 510,600 shares of the company's stock, valued at approximately $6,760,000.

Several other institutional investors have also modified their holdings of TAK. Farther Finance Advisors LLC lifted its stake in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after acquiring an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in shares of Takeda Pharmaceutical in the fourth quarter worth about $52,000. Cromwell Holdings LLC acquired a new position in shares of Takeda Pharmaceutical in the fourth quarter worth about $61,000. Venturi Wealth Management LLC lifted its stake in shares of Takeda Pharmaceutical by 554.7% in the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after acquiring an additional 4,260 shares in the last quarter. Finally, Lindbrook Capital LLC lifted its stake in shares of Takeda Pharmaceutical by 65.0% in the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock worth $68,000 after acquiring an additional 2,029 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 0.7%

NYSE TAK traded up $0.10 on Tuesday, hitting $14.67. 452,674 shares of the stock traded hands, compared to its average volume of 1,923,366. The stock has a 50-day moving average of $14.68 and a 200 day moving average of $14.02. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.43. The company has a market capitalization of $46.69 billion, a P/E ratio of 36.66, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The firm had revenue of $7.34 billion for the quarter, compared to analyst estimates of $8.02 billion. As a group, analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.